AC	Ampullary carcinoma
ASCO	American Society of Clinical Oncology
CA 19-9	Carbohydrate antigen 19-9
CAPOX	Capecitabine + oxaliplatin
CEA	Carcinoembryonic antigen
CI	Confidence interval
dMMR	Mismatch repair deficiency
DNA	Deoxyribonucleic acid
ECOG PS	Eastern Cooperative Oncology Group performance status
ESMO	European Society for Medical Oncology
EPV	Events-per-variable
FOLFIRINOX	5-fluorouracil + leucovorin + irinotecan + oxaliplatin
FOLFOX	5-fluorouracil + leucovorin + oxaliplatin
GEMOX	Gemcitabine + oxaliplatin
GI	Gastrointestinal
HR	Hazard ratio
IQR	Interquartile range
MSI-H	Microsatellite instability–high
mOS	Median overall survival
mPFS	Median progression-free survival
NCCN	National Comprehensive Cancer Network
NR	Not reached
NTRK	Neurotrophic receptor tyrosine kinase
OS	Overall survival
PFS	Progression-free survival
PFSmet	Progression-free survival in the metastatic setting
RFS	Recurrence-free survival
TMB	Tumor mutational burden
TNM	Tumor, Nodes, Metastasis